ZAGENO Blog | Essential Insights for Efficient, Innovative Labs in Life Science

How P2P Reduces Procurement Costs in Biotech and Pharma | ZAGENO

Written by ZAGENO | April 23, 2026

Life sciences organizations are increasingly expected to do more with limited resources. One of the most effective ways to improve financial performance is by increasing visibility and control over procurement spend.

Procure-to-pay (P2P) automation helps achieve this by standardizing purchasing workflows and improving financial visibility. For a full explanation of the P2P workflow for biotech and pharma, see our guide.

5 ways procure-to-pay reduces procurement costs

What cost control looks like in modern lab procurement

Cost reduction in procurement is not just about cutting expenses—it’s about creating consistency and control across every purchase.

When combined with operational improvements, these savings build on the efficiency gains from P2P automation explored in Part 1.

FAQs about P2P cost savings in biotech and pharma

  1. How does P2P reduce procurement costs?
    P2P reduces costs by enforcing supplier contracts, minimizing errors, improving spend visibility, and enabling organizations to capture discounts such as early payment incentives.
  2. What is maverick spend and why does it matter?
    Maverick spend refers to purchases made outside approved suppliers or procurement processes. It often leads to higher costs and reduced visibility into spending.
  3. Can P2P help reduce accounts payable costs?
    Yes. P2P systems automate invoice matching and streamline payment workflows, reducing processing costs and helping organizations avoid late fees or missed discounts.